A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807
Breast Diseases, Breast Neoplasms
Daphne, Alabama, United States
View Trial DetailsNCT Number: NCT02895165
The PREgnancy and FERtility (PREFER) study is a comprehensive program aiming to optimize care and improve knowledge around the topics of fertility preservation and pregnancy issues in young breast cancer patients. The program was initiated at the National Institute for Cancer Research, IRCCS AOU San Martino - IST in Genova (Liguria Region, Italy) and then it has been spread to other Italian Institutions under the umbrella of the Gruppo Italiano Mammella (GIM) study group. It is composed of two distinctive studies, one assessing fertility (i.e. PREFER-FERTILITY) and the other pregnancy (PREFER-PREGNANCY) issues. Hence, two different study protocols were developed under the umbrella of the PREFER registry.
PREFER-FERTILITY aims to obtain and centralize data about the preferences and choices of young cancer patients on the fertility preservation strategies available in Italy. Furthermore, it aims to assess the outcomes of patients undergoing one or more strategies for fertility preservation in terms of success of the techniques (i.e. recovery of ovarian function, number of cryopreserved oocytes, post-treatment pregnancies) and safety (i.e. long-term survival outcomes).
PREFER-PREGNANCY has two main objectives: 1) to obtain and centralize data on the management of breast cancer diagnosed during pregnancy, the obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments, and the long-term survival outcomes of these patients; 2) to obtain and centralize data on the clinical outcomes of breast cancer survivors that achieve a pregnancy after prior diagnosis and treatment of breast cancer.
Interested in participating?
Request Info18 year–45 year
Female
Observational
Ospedale Cardinal Massaia, Asti, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 15 years
Assessed through medical records
Time frame: 15 years
Assessed through medical records
Time frame: 15 years
Assessed through medical records
Time frame: 15 years
Assessed through an open questionnaire
Time frame: 15 years
Assessed through medical records
Time frame: 15 years
Assessed through medical records
Time frame: 15 years
Assessed through medical records
Time frame: 15 years
Time frame: 15 years
Time frame: 15 years
Time frame: 15 years
Time frame: 15 years
Time frame: 15 years
FSH (follicle stimulating hormone), estradiol and AMH (anti-mullerian hormone) serum levels assessed at baseline, during chemotherapy, at the end of chemotherapy and every six months thereafter
Time frame: 15 years
Assessed using obstetric and paediatric medical records
Time frame: 15 years
Assessed using obstetric and paediatric medical records
Contact information is provided by the study sponsor or research team.
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Other
An Italian Multicenter Prospective Cohort Study on Fertility Preservation and Pregnancy Issues in Young Breast Cancer Patients: PREgnancy and FERtilty (PREFER)
Acronym: PREFER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07060807
Breast Diseases, Breast Neoplasms
Daphne, Alabama, United States
View Trial DetailsNCT06830720
Breast Diseases, Breast Neoplasms
Wiener Neustadt, Lower Austria, Austria
View Trial DetailsNCT06312176
Breast Diseases, Breast Neoplasms
Chandler, Arizona, United States
View Trial DetailsNCT06966700
Breast Diseases, Breast Neoplasms
Gilbert, Arizona, United States
View Trial Details